GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (OTCPK:AVCTF) » Definitions » 3-Year Revenue Growth Rate

Avacta Group (Avacta Group) 3-Year Revenue Growth Rate : -3.30% (As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Avacta Group 3-Year Revenue Growth Rate?

Avacta Group's Revenue per Share for the six months ended in Jun. 2023 was $0.06.

During the past 12 months, Avacta Group's average Revenue per Share Growth Rate was 114.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -3.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was -11.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was -18.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Avacta Group was 206.60% per year. The lowest was -44.90% per year. And the median was -11.50% per year.


Competitive Comparison of Avacta Group's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Avacta Group's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avacta Group's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avacta Group's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Avacta Group's 3-Year Revenue Growth Rate falls into.



Avacta Group 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Avacta Group  (OTCPK:AVCTF) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Avacta Group 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Avacta Group's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Avacta Group (Avacta Group) Business Description

Traded in Other Exchanges
Address
Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group (Avacta Group) Headlines

From GuruFocus

Avacta's Diagnostic Division Achieves ISO 13485 Certification

By Business Wire Business Wire 07-14-2021

LG Chem Renews License Triggering Payment to Avacta

By Business Wire Business Wire 06-30-2022

Avacta announces AffyXell $7.3 Million Series A Financing

By Business Wire Business Wire 02-01-2021

Avacta Appoints COVID-19 Rapid Antigen Test Manufacturing Partner

By Business Wire Business Wire 08-06-2020

First Patient Dosed in the US in Avacta's AVA6000 Phase 1 Clinical Study

By Business Wire Business Wire 04-27-2023